marketcaparena
Search

    ALNY

    ALNYLAM PHARMACEUTICALS, INC.

    Company overview

    Market capitalization
    $34.17B
    Employees
    2,500
    Latest publication
    2026-09-29
    About ALNYLAM PHARMACEUTICALS, INC.

    Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ2 20242024-06-30 · USDQ3 20232023-09-30 · USD
    Total Revenue1,290,948,000USD1,167,175,000USD1,097,033,000USD1,249,026,000USD773,689,000USD594,189,000USD659,825,000USD750,530,000USD
    Cost Of Revenue298,261,000USD207,520,000USD267,723,000USD197,231,000USD142,029,000USD70,183,000USD68,672,000USD84,309,000USD
    Gross Profit992,687,000USD959,655,000USD829,310,000USD1,051,795,000USD631,660,000USD524,006,000USD591,153,000USD666,221,000USD
    Research Development413,134,000USD364,866,000USD372,218,000USD358,814,000USD323,621,000USD265,122,000USD294,142,000USD253,179,000USD
    Selling General Administrative347,922,000USD322,551,000USD325,374,000USD322,076,000USD323,314,000USD239,949,000USD248,397,000USD199,175,000USD
    Total Operating Expenses761,246,000USD691,019,000USD697,592,000USD683,813,000USD647,859,000USD505,929,000USD542,539,000USD452,354,000USD
    Operating Income231,441,000USD268,636,000USD131,718,000USD367,982,000USD-16,199,000USD18,077,000USD48,614,000USD213,867,000USD
    Total Other Income Expense Net-53,635,000USD-46,983,000USD29,419,000USD-129,013,000USD-19,159,000USD-59,673,000USD-59,781,000USD-63,126,000USD
    Interest Income28,143,000USD26,598,000USD26,630,000USD28,681,000USD27,486,000USD28,673,000USD29,182,000USD25,425,000USD
    Interest Expense82,051,000USD69,286,000USD129,337,000USD44,398,000USD40,246,000USD38,646,000USD33,258,000USD30,893,000USD
    Income Before Tax177,806,000USD221,653,000USD161,137,000USD238,969,000USD-35,358,000USD-41,596,000USD-11,167,000USD150,741,000USD
    Income Tax Expense13,312,000USD15,662,000USD-25,282,000USD-12,115,000USD30,919,000USD15,883,000USD5,722,000USD2,988,000USD
    Net Income164,494,000USD205,991,000USD186,419,000USD251,084,000USD-66,277,000USD-57,479,000USD-16,889,000USD147,753,000USD
    Net Interest Income——————-4,076,000USD-5,468,000USD
    Tax Provision——————5,722,000USD2,988,000USD
    Net Income From Continuing Ops——————-16,889,000USD147,753,000USD
    Ebit——————22,091,000USD181,634,000USD
    Ebitda——————37,094,000USD194,962,000USD
    Depreciation And Amortization——————15,003,000USD13,328,000USD
    Reconciled Depreciation——————24,692,000USD23,532,000USD
    Net Income Applicable To Common Shares———————147,753,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20182018-12-31 · USDFY 20142014-12-31 · USDFY 20132013-12-31 · USDFY 20122012-12-31 · USDFY 20102010-12-31 · USDFY 20092009-12-31 · USD
    Total Revenue3,713,937,000USD2,248,243,000USD74,908,000USD50,561,000USD47,167,000USD66,725,000USD100,041,000USD100,533,000USD
    Cost Of Revenue677,166,000USD306,513,000USD1,802,000USD229,775,000USD134,188,000USD122,874,000USD136,977,000USD142,652,000USD
    Gross Profit3,036,771,000USD1,941,730,000USD73,106,000USD50,561,000USD47,167,000USD66,725,000USD100,041,000USD100,533,000USD
    Research Development1,319,775,000USD1,126,232,000USD505,420,000USD190,249,000USD112,957,000USD86,569,000USD106,384,000USD108,730,000USD
    Selling General Administrative1,210,713,000USD975,526,000USD382,359,000USD44,526,000USD27,152,000USD44,612,000USD37,727,000USD39,914,000USD
    Total Operating Expenses2,535,193,000USD2,118,615,000USD887,779,000USD234,775,000USD140,109,000USD131,181,000USD144,111,000USD148,644,000USD
    Operating Income501,578,000USD-176,885,000USD-814,673,000USD-404,980,000USD-92,942,000USD-129,456,000USD-44,070,000USD-48,111,000USD
    Total Other Income Expense Net-178,426,000USD-200,490,000USD53,999,000USD4,376,000USD-47,000USD12,870,000USD1,069,000USD1,103,000USD
    Interest Income111,470,000USD121,992,000USD29,262,000USD—————
    Interest Expense252,627,000USD141,858,000USD29,262,000USD2,559,000USD1,069,000USD977,000USD2,305,000USD5,385,000USD
    Income Before Tax323,152,000USD-377,375,000USD-760,674,000USD-400,604,000USD-91,920,000USD-116,586,000USD-43,001,000USD-47,008,000USD
    Income Tax Expense9,405,000USD-99,218,000USD823,000USD-40,209,000USD-2,695,000USD-10,572,000USD514,000USD582,000USD
    Net Income313,747,000USD-278,157,000USD-761,497,000USD-360,395,000USD-89,225,000USD-106,014,000USD-43,515,000USD-47,590,000USD
    Net Interest Income——29,262,000USD—————
    Tax Provision——823,000USD—————
    Net Income From Continuing Ops——-761,497,000USD-360,395,000USD-89,225,000USD-106,014,000USD-43,515,000USD—
    Ebit——-760,674,000USD-184,214,000USD-92,942,000USD-60,749,000USD-43,001,000USD-47,008,000USD
    Ebitda——-754,239,000USD-172,288,000USD-82,713,000USD-51,714,000USD-38,060,000USD-41,016,000USD
    Depreciation And Amortization——6,435,000USD11,926,000USD10,229,000USD9,035,000USD4,941,000USD5,992,000USD
    Reconciled Depreciation——6,435,000USD—————
    Non Operating Income Net Other——53,999,000USD4,376,000USD1,022,000USD12,870,000USD1,069,000USD—
    Net Income Applicable To Common Shares——-761,497,000USD-360,395,000USD-89,225,000USD-106,014,000USD-43,515,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets5,558,769,000USD5,129,547,000USD4,966,331,000USD4,851,662,000USD4,566,019,000USD4,213,811,000USD4,239,983,000USD4,205,039,000USD
    Cash And Equivalents1,708,318,000USD1,710,779,000USD1,657,250,000USD1,490,249,000USD1,113,685,000USD1,019,654,000USD966,428,000USD—
    Total Current Assets4,620,172,000USD4,219,308,000USD4,050,662,000USD3,952,811,000USD3,643,699,000USD3,268,258,000USD3,295,285,000USD3,355,424,000USD
    Other Current Assets302,176,000USD242,103,000USD281,892,000USD188,036,000USD147,314,000USD152,420,000USD116,964,000USD145,350,000USD
    Other Non Current Assets65,132,000USD63,553,000USD59,461,000USD55,835,000USD57,172,000USD73,820,000USD65,310,000USD—
    Total Liabilities4,204,651,000USD4,054,167,000USD4,177,155,000USD4,617,768,000USD4,315,428,000USD4,098,376,000USD4,172,895,000USD—
    Total Current Liabilities1,512,513,000USD1,349,475,000USD1,466,349,000USD1,555,477,000USD1,300,847,000USD1,075,623,000USD1,186,272,000USD1,220,663,000USD
    Other Current Liabilities1,095,980,000USD946,485,000USD1,080,197,000USD1,153,648,000USD918,966,000USD704,165,000USD887,472,000USD—
    Other Non Current Liabilities9,152,000USD7,611,000USD7,594,000USD9,769,000USD10,932,000USD5,871,000USD398,108,000USD—
    Total Stockholder Equity1,354,118,000USD1,075,380,000USD789,176,000USD233,894,000USD250,591,000USD115,435,000USD67,088,000USD32,354,000USD
    Total Equity Including Noncontrolling Interest1,354,118,000USD1,075,380,000USD789,176,000USD233,894,000USD250,591,000USD115,435,000USD67,088,000USD—
    Deferred Revenue4,014,000USD3,213,000USD4,845,000USD2,541,000USD15,080,000USD28,160,000USD55,481,000USD—
    Net Receivables912,739,000USD883,957,000USD777,567,000USD964,768,000USD567,112,000USD418,035,000USD405,308,000USD353,852,000USD
    Inventory97,110,000USD84,025,000USD82,719,000USD75,383,000USD71,688,000USD65,581,000USD78,509,000USD75,987,000USD
    Property Plant Equipment Net737,502,000USD707,556,000USD708,063,000USD693,144,000USD692,192,000USD695,917,000USD693,932,000USD703,405,000USD
    Accounts Payable108,016,000USD126,628,000USD115,721,000USD117,591,000USD102,393,000USD97,399,000USD88,415,000USD70,805,000USD
    Short Term Debt45,933,000USD45,661,000USD45,518,000USD44,755,000USD46,097,000USD46,011,000USD41,886,000USD132,660,000USD
    Common Stock1,337,000USD1,334,000USD1,324,000USD1,318,000USD1,310,000USD1,303,000USD1,293,000USD1,289,000USD
    Retained Earnings-6,332,039,000USD-6,496,533,000USD-6,702,524,000USD-7,160,420,000USD-7,411,504,000USD-7,345,227,000USD-7,287,748,000USD-7,203,985,000USD
    Accumulated Other Comprehensive Income-32,138,000USD-24,894,000USD-20,097,000USD-21,775,000USD-29,952,000USD-37,517,000USD-34,518,000USD-24,826,000USD
    Cash And Short Term Investments——1,657,250,000USD1,490,249,000USD1,113,685,000USD1,026,854,000USD974,584,000USD2,780,235,000USD
    Short Term Investments——0USD0USD0USD7,200,000USD8,156,000USD1,680,315,000USD
    Deferred Revenue Non Current——————0USD—
    Total Liab———————4,172,685,000USD
    Other Current Liab———————946,168,000USD
    Capital Stock———————1,289,000USD
    Cash———————1,099,920,000USD
    Current Deferred Revenue———————71,030,000USD
    Net Debt———————1,626,273,000USD
    Short Long Term Debt Total———————2,726,193,000USD
    Long Term Debt———————1,023,654,000USD
    Property Plant Equipment Gross———————703,405,000USD
    Common Stock Shares Outstanding———————128,590,000shares
    Non Current Assets Total———————849,615,000USD
    Non Current Liabilities Total———————2,952,022,000USD
    Non Current Liabilities Other———————1,691,326,000USD
    Non Currrent Assets Other———————146,210,000USD
    Net Working Capital———————2,134,761,000USD
    Unclassified Non Current Liabilities———————237,042,000USD
    Unclassified Equity———————7,258,587,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets4,966,331,000USD4,239,983,000USD3,829,880,000USD3,546,359,000USD3,643,304,000USD3,407,061,000USD2,395,134,000USD1,574,802,000USD
    Cash And Equivalents1,657,250,000USD966,428,000USD——————
    Cash And Short Term Investments1,657,250,000USD974,584,000USD2,439,382,000USD2,192,406,000USD2,435,564,000USD1,874,395,000USD1,536,162,000USD1,082,949,000USD
    Short Term Investments0USD8,156,000USD1,626,694,000USD1,326,012,000USD1,615,589,000USD1,377,815,000USD988,984,000USD664,009,000USD
    Total Current Assets4,050,662,000USD3,295,285,000USD2,982,697,000USD2,692,247,000USD2,808,576,000USD2,614,777,000USD1,715,864,000USD1,209,319,000USD
    Other Current Assets281,892,000USD116,964,000USD126,382,000USD132,916,000USD88,078,000USD62,767,000USD80,343,000USD83,542,000USD
    Other Non Current Assets59,461,000USD65,310,000USD——————
    Total Liabilities4,177,155,000USD4,172,895,000USD——————
    Total Current Liabilities1,466,349,000USD1,186,272,000USD967,786,000USD767,915,000USD695,710,000USD585,270,000USD352,594,000USD242,837,000USD
    Other Current Liabilities1,080,197,000USD887,472,000USD——————
    Other Non Current Liabilities7,594,000USD398,108,000USD——————
    Total Stockholder Equity789,176,000USD67,088,000USD-220,644,000USD-158,223,000USD588,203,000USD1,016,247,000USD1,438,692,000USD1,301,965,000USD
    Total Equity Including Noncontrolling Interest789,176,000USD67,088,000USD——————
    Deferred Revenue4,845,000USD55,481,000USD——————
    Net Receivables777,567,000USD405,308,000USD327,787,000USD237,963,000USD198,571,000USD602,413,000USD43,011,000USD18,760,000USD
    Inventory82,719,000USD78,509,000USD89,146,000USD128,962,000USD86,363,000USD75,202,000USD56,348,000USD24,068,000USD
    Property Plant Equipment Net708,063,000USD693,932,000USD725,789,000USD738,630,000USD733,633,000USD706,514,000USD646,376,000USD320,658,000USD
    Accounts Payable115,721,000USD88,415,000USD55,519,000USD98,094,000USD73,426,000USD51,966,000USD49,884,000USD59,708,000USD
    Short Term Debt45,518,000USD41,886,000USD41,510,000USD41,967,000USD40,548,000USD36,872,000USD27,688,000USD62,885,000USD
    Common Stock1,324,000USD1,293,000USD1,259,000USD1,240,000USD1,202,000USD1,164,000USD1,122,000USD1,011,000USD
    Retained Earnings-6,702,524,000USD-7,287,748,000USD-7,009,591,000USD-6,569,349,000USD-5,438,193,000USD-4,585,369,000USD-3,727,088,000USD-2,840,972,000USD
    Accumulated Other Comprehensive Income-20,097,000USD-34,518,000USD-23,375,000USD-44,654,000USD-33,259,000USD-43,622,000USD-36,518,000USD-33,213,000USD
    Deferred Revenue Non Current—0USD——————
    Intangible Assets——697,784,000USD264,564,000USD————
    Total Liab——4,050,524,000USD3,704,582,000USD3,055,101,000USD2,390,814,000USD956,442,000USD272,837,000USD
    Other Current Liab——768,004,000USD585,749,000USD432,253,000USD369,225,000USD197,201,000USD116,290,000USD
    Capital Stock——1,259,000USD1,240,000USD1,202,000USD1,164,000USD1,122,000USD1,011,000USD
    Cash——812,688,000USD866,394,000USD819,975,000USD496,580,000USD547,178,000USD420,146,000USD
    Current Deferred Revenue——102,753,000USD42,105,000USD149,483,000USD127,207,000USD77,821,000USD3,954,000USD
    Net Debt——492,699,000USD453,854,000USD177,617,000USD24,609,000USD-243,355,000USD-390,146,000USD
    Short Long Term Debt Total——1,305,387,000USD1,320,248,000USD997,592,000USD521,189,000USD303,823,000USD92,885,000USD
    Long Term Debt——1,020,776,000USD1,016,942,000USD675,697,000USD191,278,000USD—30,000,000USD
    Property Plant Equipment Gross——948,865,000USD738,630,000USD733,633,000USD706,514,000USD425,179,000USD320,658,000USD
    Common Stock Shares Outstanding——124,906,000shares121,689,000shares118,451,000shares114,986,000shares109,264,000shares100,590,000shares
    Non Current Assets Total——847,183,000USD854,112,000USD834,728,000USD792,284,000USD679,270,000USD365,483,000USD
    Non Current Liabilities Total——3,082,738,000USD2,936,667,000USD2,359,391,000USD1,805,544,000USD603,848,000USD30,000,000USD
    Non Current Liabilities Other——1,630,686,000USD1,464,595,000USD1,683,694,000USD1,614,266,000USD603,848,000USD5,423,000USD
    Non Currrent Assets Other——111,293,000USD115,482,000USD101,095,000USD85,770,000USD18,069,000USD53,448,000USD
    Net Working Capital——2,014,911,000USD1,924,332,000USD2,112,866,000USD1,529,507,000USD1,363,270,000USD1,021,202,000USD
    Unclassified Non Current Assets——-687,683,000USD-380,046,000USD-101,095,000USD-40,725,000USD-32,894,000USD-62,071,000USD
    Unclassified Non Current Liabilities——431,276,000USD48,759,000USD-1,402,347,000USD-352,301,000USD-327,713,000USD-126,686,000USD
    Unclassified Equity——6,809,804,000USD6,453,300,000USD6,057,251,000USD5,642,910,000USD5,200,054,000USD4,174,128,000USD
    Other Liab———406,371,000USD1,402,347,000USD352,301,000USD327,713,000USD63,343,000USD
    Other Assets———115,482,000USD101,095,000USD40,725,000USD32,894,000USD53,448,000USD
    Net Tangible Assets———-158,223,000USD588,203,000USD1,016,247,000USD1,438,692,000USD1,301,965,000USD
    Long Term Investments——————14,825,000USD0USD
    Deferred Long Term Liab———————57,920,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Stock Based Compensation86,625,000USD70,154,000USD71,632,000USD108,211,000USD111,680,000USD56,712,000USD91,645,000USD45,804,000USD
    Deferred Income Tax2,657,000USD9,310,000USD-27,170,000USD5,598,000USD9,735,000USD9,639,000USD——
    Change To Account Receivables-31,602,000USD-110,421,000USD184,247,000USD-399,863,000USD-136,913,000USD-7,434,000USD-59,508,000USD-37,092,000USD
    Change To Inventory280,000USD-3,324,000USD-13,861,000USD4,976,000USD11,144,000USD6,215,000USD849,000USD5,925,000USD
    Change To Liabilities61,617,000USD-176,033,000USD-174,854,000USD223,509,000USD182,148,000USD-155,737,000USD——
    Change In Working Capital-29,074,000USD-296,101,000USD-75,458,000USD-192,120,000USD63,156,000USD-189,725,000USD-74,212,000USD30,729,000USD
    Operating Cash Flow326,724,000USD70,504,000USD163,555,000USD325,109,000USD153,730,000USD-118,314,000USD——
    Capital Expenditures-34,680,000USD-21,833,000USD-23,292,000USD-12,142,000USD-14,293,000USD-8,970,000USD-9,094,000USD-4,192,000USD
    Net Investments-302,877,000USD-48,434,000USD-13,874,000USD515,399,000USD-127,088,000USD122,739,000USD——
    Unclassified Investing Cash Flow-51,800,000USD44,725,000USD————9,211,000USD23,392,000USD
    Investing Cash Flow-363,457,000USD-25,542,000USD-37,166,000USD501,107,000USD-141,381,000USD113,769,000USD——
    Common Stock Issuance33,561,000USD13,157,000USD41,701,000USD77,740,000USD81,222,000USD49,365,000USD——
    Other Financing Activities-6,000USD-9,000USD——————
    Unclassified Financing Cash Flow2,682,000USD2,566,000USD3,616,000USD-526,088,000USD-27,465,000USD-5,281,000USD36,278,000USD108,036,000USD
    Financing Cash Flow36,237,000USD15,714,000USD45,317,000USD-448,348,000USD53,757,000USD44,084,000USD——
    Effect Of Forex Changes On Cash-2,445,000USD-7,064,000USD-5,701,000USD-927,000USD27,506,000USD14,058,000USD——
    Change In Cash-2,941,000USD53,612,000USD166,005,000USD376,941,000USD93,612,000USD53,597,000USD-133,846,000USD131,305,000USD
    End Cash Flow1,709,478,000USD1,712,419,000USD1,658,807,000USD1,492,802,000USD1,115,861,000USD1,022,249,000USD——
    Net Income——————-83,763,000USD-111,570,000USD
    Depreciation——————-20,546,000USD48,696,000USD
    Other Non Cash Items——————-7,786,000USD30,048,000USD
    Total Cash From Operating Activities——————-94,662,000USD43,707,000USD
    Free Cash Flow——————-103,756,000USD39,515,000USD
    Investments——————-52,910,000USD-30,250,000USD
    Total Cashflows From Investing Activities——————-52,910,000USD-30,250,000USD
    Total Cash From Financing Activities——————30,997,000USD102,755,000USD
    Begin Period Cash Flow——————1,102,498,000USD968,492,000USD
    End Period Cash Flow——————968,652,000USD1,102,498,000USD
    Other Cashflows From Investing Activities——————-117,000USD-19,200,000USD
    Other Cashflows From Financing Activities——————-5,281,000USD-5,281,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USD
    Stock Based Compensation156,779,000USD276,603,000USD168,392,000USD
    Deferred Income Tax11,967,000USD24,972,000USD19,374,000USD
    Change To Account Receivables-142,023,000USD-544,210,000USD-144,347,000USD
    Change To Inventory-3,044,000USD22,335,000USD17,359,000USD
    Change To Liabilities-114,416,000USD249,920,000USD26,411,000USD
    Change In Working Capital-325,175,000USD-318,689,000USD-126,569,000USD
    Operating Cash Flow397,228,000USD360,525,000USD35,416,000USD
    Capital Expenditures-56,513,000USD-35,405,000USD-23,263,000USD
    Net Investments-351,311,000USD511,050,000USD-4,349,000USD
    Other Investing Activities25,900,000USD2,150,000USD—
    Unclassified Investing Cash Flow-7,075,000USD-4,300,000USD—
    Investing Cash Flow-388,999,000USD473,495,000USD-27,612,000USD
    Common Stock Issuance46,718,000USD208,327,000USD130,587,000USD
    Other Financing Activities-15,000USD——
    Unclassified Financing Cash Flow5,248,000USD-558,834,000USD-32,746,000USD
    Financing Cash Flow51,951,000USD-350,507,000USD97,841,000USD
    Effect Of Forex Changes On Cash-9,509,000USD40,637,000USD41,564,000USD
    Change In Cash50,671,000USD524,150,000USD147,209,000USD
    End Cash Flow1,709,478,000USD1,492,802,000USD1,115,861,000USD
    Other Non Cash Items—-39,146,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Depreciation54,800,000USD55,100,000USD97,031,000USD85,550,000USD89,694,000USD74,435,000USD54,368,000USD6,435,000USD
    Stock Based Compensation348,235,000USD272,084,000USD221,680,000USD230,649,000USD165,717,000USD139,873,000USD174,841,000USD157,752,000USD
    Deferred Income Tax-2,198,000USD-106,762,000USD——————
    Other Non Cash Items-42,473,000USD0USD214,928,000USD309,236,000USD174,238,000USD95,755,000USD-12,613,000USD-6,841,000USD
    Change To Account Receivables-359,963,000USD-86,550,000USD-87,939,000USD-45,597,000USD-101,799,000USD-56,236,000USD-24,238,000USD15,242,000USD
    Change To Inventory8,474,000USD13,590,000USD18,367,000USD-34,136,000USD-26,415,000USD-35,426,000USD-32,411,000USD-22,645,000USD
    Change To Liabilities75,066,000USD91,093,000USD—191,769,000USD88,240,000USD143,732,000USD92,354,000USD74,835,000USD
    Change In Working Capital-394,147,000USD21,362,000USD10,759,000USD-35,553,000USD-162,823,000USD-12,701,000USD402,381,000USD45,099,000USD
    Operating Cash Flow524,080,000USD-8,312,000USD——————
    Capital Expenditures-58,697,000USD-34,277,000USD-62,211,000USD-72,059,000USD-76,372,000USD-70,361,000USD-140,156,000USD-126,887,000USD
    Net Investments497,176,000USD-63,246,000USD——————
    Other Investing Activities2,150,000USD117,000USD——————
    Unclassified Investing Cash Flow-4,300,000USD-19,434,000USD-34,096,000USD85,253,000USD————
    Investing Cash Flow436,329,000USD-116,840,000USD——————
    Common Stock Issuance250,028,000USD302,951,000USD——————
    Unclassified Financing Cash Flow-555,218,000USD-8,792,000USD147,464,000USD——-200,484,000USD-71,284,000USD33,469,000USD
    Financing Cash Flow-305,190,000USD294,159,000USD——————
    Effect Of Forex Changes On Cash34,936,000USD-15,239,000USD——————
    Change In Cash690,155,000USD153,768,000USD-53,672,000USD46,403,000USD323,107,000USD-50,582,000USD126,997,000USD-224,201,000USD
    End Cash Flow1,658,807,000USD968,652,000USD——————
    Net Income——-440,242,000USD-1,131,156,000USD-852,824,000USD-858,281,000USD-886,116,000USD-761,497,000USD
    Total Cash From Operating Activities——104,156,000USD-541,274,000USD-641,693,000USD-614,961,000USD-278,427,000USD-562,616,000USD
    Free Cash Flow——41,945,000USD-613,333,000USD-718,065,000USD-685,322,000USD-418,583,000USD-689,503,000USD
    Investments——-235,605,000USD169,354,000USD-192,564,000USD-333,957,000USD-300,521,000USD414,657,000USD
    Total Cashflows From Investing Activities——-336,350,000USD169,354,000USD-273,300,000USD-435,518,000USD-417,677,000USD272,945,000USD
    Net Borrowings——0USD254,004,000USD500,000,000USD200,000,000USD-30,000,000USD-30,000,000USD
    Total Cash From Financing Activities——172,131,000USD425,753,000USD1,247,118,000USD994,979,000USD823,184,000USD65,470,000USD
    Begin Period Cash Flow——868,556,000USD822,153,000USD499,046,000USD549,628,000USD422,631,000USD646,832,000USD
    End Period Cash Flow——814,884,000USD868,556,000USD822,153,000USD499,046,000USD549,628,000USD422,631,000USD
    Other Cashflows From Investing Activities——-4,438,000USD-13,194,000USD-4,364,000USD-31,200,000USD23,000,000USD-14,825,000USD
    Other Cashflows From Financing Activities——24,667,000USD-87,611,000USD500,850,000USD695,481,000USD71,284,000USD65,470,000USD
    Sale Purchase Of Stock———259,360,000USD246,268,000USD299,982,000USD853,184,000USD-3,469,000USD
    Issuance Of Capital Stock———0USD0USD99,498,000USD781,900,000USD0USD
    Cash And Cash Equivalents Changes———53,833,000USD332,125,000USD-55,500,000USD127,080,000USD-224,201,000USD
    Unclassified Operating Cash Flow————-55,695,000USD-54,042,000USD-11,288,000USD—
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2024Quarterly · 2024-03-31ProductAmvuttra — GIVLAARI58,056,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductAmvuttra — ONPATTRO69,217,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductAmvuttra — OXLUMO42,649,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductAmvuttra — Research Services Obligation14,700,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductAmvuttra — Royalty10,622,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductC5Co Co Obligation700,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductC5License Obligation1,700,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductCollaborations118,548,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductDevelopment Services Obligation7,151,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductLicense Obligation65,000,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductOther105,990,000USD0001178670-24-000023
    Q1 2024Quarterly · 2024-03-31ProductTechnology Transfer Obligation0USD0001178670-24-000023
    Q3 2023Quarterly · 2023-09-30ProductAmvuttra148,680,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductC5Co Co Obligation2,000,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductC5License Obligation700,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductDevelopment Services Obligation200,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductGIVLAARI54,148,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductLicense Obligation310,000,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductONPATTRO81,589,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductOther41,572,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductOXLUMO28,736,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductResearch Services Obligation73,000,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductRoyalty9,905,000USD0001178670-23-000023
    Q3 2023Quarterly · 2023-09-30ProductTechnology Transfer Obligation0USD0001178670-23-000023
    Q2 2023Quarterly · 2023-06-30ProductAmvuttra132,136,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductC5License Obligation3,100,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductCollaborations5,844,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductDevelopment Services Obligation0USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductGIVLAARI57,899,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductLicense Obligation0USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductONPATTRO91,458,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductOther13,900,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductOXLUMO24,212,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductResearch Services Obligation-17,000,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductRoyalty7,205,000USD0001178670-24-000041
    Q2 2023Quarterly · 2023-06-30ProductTechnology Transfer Obligation0USD0001178670-24-000041
    FY 2022Yearly · 2022-12-31ProductAmvuttra93,795,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductC5License Obligation32,500,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductGIVLAARI173,144,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductONPATTRO557,608,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductOther73,812,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductOXLUMO69,782,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductResearch Services Obligation28,600,000USD0001178670-23-000005
    FY 2022Yearly · 2022-12-31ProductRoyalty8,177,000USD0001178670-23-000005
    Q3 2022Quarterly · 2022-09-30ProductAmvuttra25,229,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductC5License Obligation1,400,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductGIVLAARI45,659,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductONPATTRO144,950,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductOther17,597,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductOXLUMO16,429,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductResearch Services Obligation10,300,000USD0001178670-22-000026
    Q3 2022Quarterly · 2022-09-30ProductRoyalty2,742,000USD0001178670-22-000026
    Q2 2022Quarterly · 2022-06-30ProductAmvuttra0USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductC5Co Co Obligation1,700,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductC5License Obligation-4,800,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductCollaborations9,025,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductGIVLAARI45,150,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductONPATTRO153,428,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductOther1,500,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductOXLUMO14,937,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductResearch Services Obligation1,600,000USD0001178670-23-000015
    Q2 2022Quarterly · 2022-06-30ProductRoyalty2,278,000USD0001178670-23-000015
    Q1 2022Quarterly · 2022-03-31ProductC5License Obligation1,300,000USD0001178670-22-000016
    Q1 2022Quarterly · 2022-03-31ProductGIVLAARI35,277,000USD0001178670-22-000016
    Q1 2022Quarterly · 2022-03-31ProductONPATTRO137,009,000USD0001178670-22-000016
    Q1 2022Quarterly · 2022-03-31ProductOther17,445,000USD0001178670-22-000016
    Q1 2022Quarterly · 2022-03-31ProductOXLUMO14,586,000USD0001178670-22-000016
    Q1 2022Quarterly · 2022-03-31ProductResearch Services Obligation7,200,000USD0001178670-22-000016
    Q1 2022Quarterly · 2022-03-31ProductRoyalty442,000USD0001178670-22-000016
    Q4 2021Quarterly · 2021-12-31ProductC5License Obligation14,200,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductGIVLAARI40,679,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductONPATTRO138,630,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductOther36,725,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductOXLUMO19,205,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductResearch Services Obligation8,700,000USDLegacy provider
    Q4 2021Quarterly · 2021-12-31ProductRoyalty396,000USDLegacy provider
    FY 2021Yearly · 2021-12-31ProductAmvuttra0USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductC5License Obligation44,600,000USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductGIVLAARI127,815,000USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductONPATTRO474,737,000USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductOther98,753,000USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductOXLUMO59,586,000USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductResearch Services Obligation37,600,000USD0001178670-23-000005
    FY 2021Yearly · 2021-12-31ProductRoyalty1,196,000USD0001178670-23-000005
    Q3 2021Quarterly · 2021-09-30ProductAmvuttra0USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductC5License Obligation1,200,000USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductGIVLAARI31,833,000USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductONPATTRO120,317,000USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductOther10,036,000USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductOXLUMO14,894,000USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductResearch Services Obligation8,900,000USD0001178670-22-000026
    Q3 2021Quarterly · 2021-09-30ProductRoyalty453,000USD0001178670-22-000026
    FY 2020Yearly · 2020-12-31ProductAmvuttra0USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductC5License Obligation7,100,000USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductGIVLAARI55,106,000USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductONPATTRO306,081,000USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductOther79,433,000USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductOXLUMO333,000USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductResearch Services Obligation44,800,000USD0001178670-23-000005
    FY 2020Yearly · 2020-12-31ProductRoyalty0USD0001178670-23-000005

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.